Close



Sep 21, 2023 10:00AM
Sep 15, 2023 09:29AM
Sep 15, 2023 09:29AM
Jun 22, 2023 08:00AM
Apr 26, 2023 04:03PM
Mar 14, 2023 08:00AM
Mar 7, 2023 04:08PM BioMarin Pharma (BMRN) Announces FDA Accepts sNDA to Expand Use of VOXZOGO for Injection to Treat Children with Achondroplasia Under the Age of 5
Mar 7, 2023 04:05PM
Mar 7, 2023 07:07AM
Mar 6, 2023 07:28PM
Feb 27, 2023 04:03PM
Jan 9, 2023 05:05AM
Jan 8, 2023 11:00AM
Jan 4, 2023 08:39AM BioMarin (BMRN) PT Raised to $200 at BofA Securities, Added to US 1 List
Nov 7, 2022 04:31PM
Nov 7, 2022 04:30PM
Oct 26, 2022 04:03PM
Oct 12, 2022 05:12PM
Oct 12, 2022 04:05PM
Oct 12, 2022 04:05PM
Feb 9, 2022 08:31AM BioMarin Pharma (BMRN) Sells Priority Review Voucher for $110 Million
Feb 9, 2022 08:31AM
Oct 28, 2021 06:20AM
Oct 27, 2021 04:05PM
Aug 27, 2021 09:51AM
Aug 27, 2021 09:02AM
Aug 27, 2021 09:01AM
Aug 24, 2021 07:20AM BioMarin Pharmaceutical Inc. (BMRN) Likely to Get EU Approval of Voxzogo in Next 10 Days, Opening a $4.4B Opportunity - Cowen
Jul 28, 2021 04:03PM
Jun 25, 2021 07:30AM
Jun 25, 2021 07:29AM
Jun 22, 2021 07:15AM
Apr 29, 2021 04:03PM
Apr 15, 2021 08:35AM
Apr 15, 2021 08:31AM BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and P
Mar 20, 2021 11:15AM
Mar 3, 2021 08:32AM
Mar 3, 2021 08:31AM
Feb 25, 2021 04:05PM
Dec 21, 2020 08:38AM
Dec 21, 2020 08:29AM
Nov 5, 2020 04:05PM BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
Nov 2, 2020 08:55PM
Aug 5, 2020 09:46AM
Aug 4, 2020 04:05PM
Jun 17, 2020 09:22AM
Jun 17, 2020 09:20AM
Jun 10, 2020 07:13AM
Jun 1, 2020 05:57AM BioMarin Pharma (BMRN) Highlights 4-Yrs of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia
May 31, 2020 04:01PM

12,348 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All